Literature DB >> 25046247

Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β-catenin signaling pathway.

Fu-Ming Zi1, Jing-Song He1, Yi Li1, Cai Wu1, Wen-Jun Wu1, Yang Yang1, Li-Juan Wang1, Dong-Hua He1, Li Yang1, Yi Zhao1, Gao-Feng Zheng1, Xiao-Yan Han1, He Huang1, Qing Yi2, Zhen Cai1.   

Abstract

Multiple myeloma (MM) is a malignant plasma cells proliferative disease. The intricate cross-talk of myeloma cells with bone marrow microenvironment plays an important role in facilitating growth and survival of myeloma cells. Bone marrow mesenchymal stem cells (BMMSCs) are important cells in MM microenvironment. In solid tumors, BMMSCs can be educated by tumor cells to become cancer-associated fibroblasts (CAFs) with high expression of fibroblast activation protein (FAP). FAP was reported to be involved in drug resistance, tumorigenesis, neoplastic progression, angiogenesis, invasion, and metastasis of tumor cells. However, the expression and the role of FAP in MM bone marrow microenvironment are still less known. The present study is aimed to investigate the expression of FAP, the role of FAP, and its relevant signaling pathway in regulating apoptosis induced by bortezomib in MM cells. In this study, our data illustrated that the expression levels of FAP were not different between the cultured BMMSCs isolated from MM patients and normal donors. The expression levels of FAP can be increased by tumor cells conditioned medium (TCCM) stimulation or coculture with RPMI8226 cells. FAP has important role in BMMSCs mediated protecting MM cell lines from apoptosis induced by bortezomib. Further study showed that this process may likely through β-catenin signaling pathway in vitro. The activation of β-catenin in MM cell lines was dependent on direct contact with BMMSCs other than separated by transwell or additional condition medium from BMMSCs and cytokines.

Entities:  

Keywords:  apoptosis; bone marrow mesenchymal stem cells; cancer-associated fibroblast; fibroblast activation protein; multiple myeloma; signaling pathway; β-catenin

Mesh:

Substances:

Year:  2014        PMID: 25046247      PMCID: PMC4130734          DOI: 10.4161/cbt.29924

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  76 in total

1.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

Authors:  M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

2.  A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.

Authors:  William G Gunn; Adam Conley; Lisa Deininger; Scott D Olson; Darwin J Prockop; Carl A Gregory
Journal:  Stem Cells       Date:  2005-11-17       Impact factor: 6.277

3.  Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells.

Authors:  Siqing Wang; Sungyoul Hong; Jing Yang; Jianfei Qian; Xiang Zhang; Elizabeth Shpall; Larry W Kwak; Qing Yi
Journal:  Blood       Date:  2006-08-17       Impact factor: 22.113

4.  Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line.

Authors:  Xin Maggie Wang; Denise Ming Tse Yu; Geoffrey W McCaughan; Mark D Gorrell
Journal:  Hepatology       Date:  2005-10       Impact factor: 17.425

Review 5.  The role of the bone marrow microenvironment in multiple myeloma.

Authors:  H R De Raeve; K Vanderkerken
Journal:  Histol Histopathol       Date:  2005-10       Impact factor: 2.303

6.  Wnts induce migration and invasion of myeloma plasma cells.

Authors:  Ya-Wei Qiang; Katie Walsh; Lei Yao; Noemi Kedei; Peter M Blumberg; Jeffrey S Rubin; John Shaughnessy; Stuart Rudikoff
Journal:  Blood       Date:  2005-05-10       Impact factor: 22.113

7.  Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma.

Authors:  B Arnulf; S Lecourt; J Soulier; B Ternaux; M-Noelle Lacassagne; A Crinquette; J Dessoly; A-K Sciaini; M Benbunan; C Chomienne; J-P Fermand; J-P Marolleau; J Larghero
Journal:  Leukemia       Date:  2006-11-09       Impact factor: 11.528

8.  Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis.

Authors:  Pinak S Acharya; Alicia Zukas; Vishal Chandan; Anna-Luise A Katzenstein; Ellen Puré
Journal:  Hum Pathol       Date:  2006-03       Impact factor: 3.466

9.  Bone marrow mesenchymal stem cells are abnormal in multiple myeloma.

Authors:  J Corre; K Mahtouk; M Attal; M Gadelorge; A Huynh; S Fleury-Cappellesso; C Danho; P Laharrague; B Klein; T Rème; P Bourin
Journal:  Leukemia       Date:  2007-03-08       Impact factor: 11.528

10.  Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes.

Authors:  Stefan Bauer; Michael C Jendro; Andreas Wadle; Sascha Kleber; Frank Stenner; Robert Dinser; Anja Reich; Erica Faccin; Stefan Gödde; Harald Dinges; Ulf Müller-Ladner; Christoph Renner
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more
  10 in total

1.  Detection and screening of small molecule agents for overcoming Sorafenib resistance of hepatocellular carcinoma: a bioinformatics study.

Authors:  Jinli Lv; Bo Zhu; Liang Zhang; Qichao Xie; Wenlei Zhuo
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.

Authors:  Chorom Pak; Natalie S Callander; Edmond W K Young; Benjamin Titz; KyungMann Kim; Sandeep Saha; Kenny Chng; Fotis Asimakopoulos; David J Beebe; Shigeki Miyamoto
Journal:  Integr Biol (Camb)       Date:  2015-05-22       Impact factor: 2.192

3.  Fibroblast activation protein in osteosarcoma cells promotes angiogenesis via AKT and ERK signaling pathways.

Authors:  Chao Zeng; Ming Wen; Xiaomei Liu
Journal:  Oncol Lett       Date:  2018-02-12       Impact factor: 2.967

4.  Effects of β-catenin on differentially expressed genes in multiple myeloma.

Authors:  Hui Chen; Wei Chai; Bin Li; Ming Ni; Guo-Qiang Zhang; Hua-Wei Liu; Zhuo Zhang; Ji-Ying Chen; Yong-Gang Zhou; Yan Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-07-31

5.  Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients.

Authors:  Catherine Meyer; Magnus Dahlbom; Thomas Lindner; Sebastien Vauclin; Christine Mona; Roger Slavik; Johannes Czernin; Uwe Haberkorn; Jeremie Calais
Journal:  J Nucl Med       Date:  2019-12-13       Impact factor: 10.057

6.  Fibroblast activation protein-α promotes the growth and migration of lung cancer cells via the PI3K and sonic hedgehog pathways.

Authors:  Jun Jia; Tracey A Martin; Lin Ye; Lin Meng; Nan Xia; Wen G Jiang; Xiaodong Zhang
Journal:  Int J Mol Med       Date:  2017-10-27       Impact factor: 4.101

7.  MM-BMSCs induce naïve CD4+ T lymphocytes dysfunction through fibroblast activation protein α.

Authors:  Xiaofei Wu; Yadan Wang; Jian Xu; Ting Luo; Jun Deng; Yu Hu
Journal:  Oncotarget       Date:  2017-04-30

8.  Interleukin-32α promotes the proliferation of multiple myeloma cells by inducing production of IL-6 in bone marrow stromal cells.

Authors:  Xuanru Lin; Li Yang; Gang Wang; Fuming Zi; Haimeng Yan; Xing Guo; Jing Chen; Qingxiao Chen; Xi Huang; Yi Li; Enfan Zhang; Wenjun Wu; Yang Yang; Donghua He; Jingsong He; Zhen Cai
Journal:  Oncotarget       Date:  2017-10-07

Review 9.  Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics.

Authors:  Ellen Puré; Rachel Blomberg
Journal:  Oncogene       Date:  2018-05-03       Impact factor: 9.867

Review 10.  Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.

Authors:  Roberto Ria; Angelo Vacca
Journal:  Int J Mol Sci       Date:  2020-01-17       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.